Abstracts tagged "spondyloarthritis"

Abstract Number: 0364 • ACR Convergence 2023
Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis
Adam Mayer¹, Timothy G. Brandon², Pamela F. Weiss³ and on behalf of the JAXSPERT members², ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The extent to which heterogeneity exists in youth with axial disease and juvenile spondyloarthritis (JSpA) is unclear. In a cross-sectional sample of patients classified…
Abstract Number: 0522 • ACR Convergence 2023
Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status
Xenofon Baraliakos¹, Désirée van der Heijde², Pedro Machado³, Victoria Navarro-Compán⁴, Lianne Gensler⁵, Patricia Pertel⁶, Erhard Quebe-Fehling⁶, Aimee Readie⁷, Hanno Richards⁶ and Denis Poddubnyy⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, Immunology, East Hanover, NJ, ⁸Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: SURPASS, a phase 3b randomized controlled study in patients with radiographic axial spondyloarthritis (r-axSpA), found low spinal radiographic progression over 2 years with no…
Abstract Number: 0829 • ACR Convergence 2023
Decreased History of Breastfeeding During Infancy in Juvenile Spondyloarthritis: A Case-Control Study
Katelyn Baggett¹, Timothy G. Brandon², Rui Xiao³ and Pamela F. Weiss⁴, ¹Penn State College of Medicine, Newtown Square, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Pediatrics Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The pathogenesis of juvenile spondyloarthritis (JSpA) is multifactorial, and includes a genetic predisposition of the HLA-B27 allele, and environmental exposures such as the microbiome.…
Abstract Number: 1390 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients suffering from ankylosing spondylitis (AS) in randomized clinical trials [1]. There is only limited…
Abstract Number: 1436 • ACR Convergence 2023
Secukinumab Demonstrates a Consistent Safety Profile in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Updated Pooled Safety Analysis from Clinical Trials
Atul Deodhar¹, Iain McInnes², Xenofon Baraliakos³, Alice B. Gottlieb⁴, Uta Kiltz⁵, Stefan Schreiber⁶, Braja Gopal Sahoo⁷, Weibin Bao⁸, Hanno Richards⁹, Luminita Pricop¹⁰, Corine Gaillez¹¹, Victor Dong¹⁰ and Philip J. Mease¹², ¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ²University of Glasgow, Glasgow, United Kingdom, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶University Hospital Schleswig-Holstein, Kiel, Germany, ⁷Novartis Healthcare Pvt, Hyderabad, India, ⁸Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Croissy Sur Seine, France, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Pooled safety data have been reported for secukinumab administration in patients with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).1,2 The aim of…
Abstract Number: 1880 • ACR Convergence 2023
Performance of Machine Learning Algorithms in Discriminating Spondyloarthritis Features on Magnetic Resonance Imaging: A Systematic Review and Meta-analysis
Sun Jae Moon¹, Seulkee Lee¹, Seonyoung Kang¹, Hyungjin Kim¹, Jaejoon Lee¹, Jinseok kim², Eun-Mi Koh³, Jinseub Hwang⁴ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea, ³Health Insurance Review and Assessment Service, Seoul, South Korea, ⁴Department of Data Science, Daegu University, Gyeongsan, South Korea
Background/Purpose: The diagnostic role of Magnetic Resonance Imaging (MRI) for axial spondyloarthritis(axSpA) has grown since introducing the ASAS criteria for axSpA. Recent advances in machine…
Abstract Number: 2206 • ACR Convergence 2023
Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis
Eric Toussirot¹, Caroline Laheurte², Eléonore Gravelin², Charline Vauchy³, Marc Puyraveau³ and Philippe Saas⁴, ¹University Hospital of Besancon, Besançon, France, ²INSERM UMR1098, plateforme de biomonitoring, EFS Bourgogne-Franche-Comté, Besançon, France, ³INSERM CIC-1431, Besançon, France, ⁴INSERM UMR1098, EFS Bourgogne-Franche-Comté, Besançon, France
Background/Purpose: MAIT (mucosal associated invariant T) cells are involved in mucosa defense against bacteria. This cellular subset is characterized by a semi-invariant αβ TCR and…
Abstract Number: 2224 • ACR Convergence 2023
Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes
FERNANDO MONTERO¹, Laura Berbel Arcobé², Karen Carpio Astudillo¹, Jose Maria Bellón³ and Xavier Juanola Roura⁴, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²H.U. Bellvitge, Barcelona, Spain, ³Gregorio Marañón Health Research Institute, Madrid, Spain, ⁴Hospital Universitari de Bellvitge, Barcelona, Spain
Background/Purpose: The term "Difficult-to-Treat" (D2T) defines those patients who remain active despite having undergone various treatments within the established recommendations. This concept is defined by…
Abstract Number: 0370 • ACR Convergence 2023
Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis
Melissa Oliver¹, Kelly Mosesso², Pamela F. Weiss³, Robert Colbert⁴, Matthew Stoll⁵ and Hemalatha Srinivasalu⁶, ¹Indiana University, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴NIH/NIAMS, Bethesda, MD, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Children's National Hospital, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in children with juvenile spondyloarthritis (JSpA) and generally represent the first-line choice for biologic therapy. However, not…
Abstract Number: 0523 • ACR Convergence 2023
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Fabian Proft¹, Désirée van der Heijde², Xenofon Baraliakos³, Joerg Ermann⁴, Carmen Fleurinck⁵, Ute Massow⁶, Natasha De Peyrecave⁷, Vanessa Taieb⁸, Astrid van Tubergen⁹ and Victoria Navarro-Compán¹⁰, ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Colombes, France, ⁹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, ¹⁰Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic rheumatic disease which requires optimal management and disease control. Patients (pts) can experience loss of response in the…
Abstract Number: 0841 • ACR Convergence 2023
Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis
Maureen Dubreuil¹, Abhijeet Danve², Swetha Ann Alexander³, Mohamad Bittar⁴, Liana Fraenkel⁵, Alyssa Grimshaw⁶, Anand Kumthekar⁷, Michael LaValley⁸, Jean liew⁹, Marina Nighat Magrey¹⁰, Vikas Majithia¹¹, Sali Merjanah¹², Hillary Norton¹³, Jessica A Walsh¹⁴ and Atul Deodhar¹⁵, ¹Department of Rheumatology, Boston University School of Medicine, Milton, MA, ²Yale University School of Medicine, Glastonbury, CT, ³University of Utah Health, Salt Lake City, UT, ⁴The University of Tennessee Health Science Center, Memphis, TN, ⁵Berkshire Health Systems, Lenox, MA, ⁶Yale University, New Haven, CT, ⁷Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁸Boston University School of Public Health, Arlington, MA, ⁹Boston University, Boston, MA, ¹⁰Case Western Reserve University, University Hospitals, Cleveland, OH, ¹¹Mayo Clinic Florida, Jacksonville, FL, ¹²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ¹³Inspire Santa Fe Rheumatology, Santa Fe, NM, ¹⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ¹⁵Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: In the United States (US), the diagnosis of axial spondyloarthritis (axSpA) continues to be delayed by an average of 10 years from symptom onset.…
Abstract Number: 1391 • ACR Convergence 2023
Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care
Franziska Neinert¹, Imke Redeker², Styliani Tsiami¹, David Kiefer¹, Barbara Guminski¹, Xenofon Baraliakos³, Juergen Braun¹ and Uta Kiltz⁴, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²Ruhr Universität Bochum, Bochum, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Achieving remission is the treatment target for patients (pts.) with axial spondyloarthritis (axSpA).Remission rates over longer periods in a real-life setting have not been…
Abstract Number: 1644 • ACR Convergence 2023
The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients
Alba Boix-Amorós¹, Rebecca Blank², Adam Cantor¹, Jesus Sanz³, Ana Gutiérrez-Casbas⁴, Jordi Gratacos Masmitja⁵, Iago Rodríguez -Lago⁶, Elisa Trujillo⁷, Ignacio Marin-Jimenez⁸, Zulema Plaza⁹, Marta Domínguez¹⁰, Jose Federico Diaz-Gonzalez¹¹, Juan D Canete¹², Jose Scher¹³ and Jose Clemente¹, ¹Icahn School of Medicine, New York, NY, ²New York University, New York, NY, ³Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ⁴Hospital General Universitario Dr. Balmis, Alicante, Spain, ⁵University Hospital Parc Taulí, Sabadell, Spain, ⁶Gastroenterology department Hospital Galdakao, Galdakao, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Public Health System, Madrid, Spain, ⁹Universidad Autónoma de Madrid, Madrid, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Universitario de Canarias, La Laguna, Spain, ¹²Hospital Clinic an IDIBAPS, Barcelona, Spain, ¹³New York University School of Medicine, New York, NY
Background/Purpose: Nearly 8% of patients with spondyloarthritis (SpA) manifest symptoms that are compatible with active inflammatory bowel disease (IBD), despite not having any previous diagnosis…
Abstract Number: 1886 • ACR Convergence 2023
Costotransverse Joint Ankylosis and Association with Syndesmophyte Progression in Patients with Radiographic Axial Spondyloarthritis
Hong Ki Min¹, Se Hee Kim², Hae-Rim Kim³, Sang-Heon Lee¹ and Sang-Hoon Lee², ¹Konkuk University School of Medicine, Seoul, South Korea, ²Kyung Hee University Hospital at Gangdong, Seoul, South Korea, ³Rheumatology, Konkuk University Medical Center, Seoul, South Korea
Background/Purpose: Costotransverse joint ankylosis in radiographic axial spondyloarthritis (r-axSpA) patients was measured. Furthermore, the association between syndesmophyte progression assessed by CT syndesmophyte score (CTSS) and…
Abstract Number: 2207 • ACR Convergence 2023
Knowledge, Awareness, and Attitudes Regarding Inflammatory Back Pain Among Non-Rheumatology Physicians in the United States
William Odell¹, Swetha Ann Alexander², Nicolas Page³, Narinder Maheshwari⁴ and Abhijeet Danve⁵, ¹Yale University, Wethersfield, CT, ²University of Utah Health, Salt Lake City, UT, ³Yale University, New Haven, CT, ⁴UCONN Health, Farmington, CT, ⁵Yale University School of Medicine, Glastonbury, CT
Background/Purpose: Inflammatory back pain (IBP) is the defining feature of axial spondyloarthritis (axSpA). However, it may be difficult for non-rheumatology physicians (non-rheums) to distinguish between…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].